

Structure Elucidation and Cholinesterase Inhibition Activity of Two New Minor Amaryllidaceae Alkaloids

Jana Maříková¹, Abdullah Al Mamun², Latifah Al Shammari², Jan Korábečný^{3,4}, Tomáš Kučera³, Daniela Hulcová^{2,5}, Jiří Kuneš¹, Milan Malaník⁶, Michaela Vašková⁷, Eliška Kohelová², Lucie Nováková⁸, Lucie Cahlíková², and Milan Pour^{1,*}

- ¹ Department of Bioorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Kralove, Czech Republic; marikoj2@faf.cuni.cz (J.M.); kunes@faf.cuni.cz (J.K.)
- ² ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Kralove, Czech Republic; almamuna@faf.cuni.cz (A.A.M.); alshamml@faf.cuni.cz (L.A.S.); kohelove@faf.cuni.cz (E.K.); cahlikova@faf.cuni.cz (L.C.)
- ³ Department of Toxicology and Military Pharmacy, University of Defence, Trenesska 1575, 500 05 Hradec Kralove, Czech Republic; tomas.kucera2@unob.cz (T.K.)
- ⁴ Biomedical Research Centre, University Hospital Hradec Králové, Sokolska 581, 500 05 Hradec Kralove, Czech Republic; jan.korabecny@fnhk.cz (J.Ko.)
- ⁵ Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Kralove, Czech Republic; hulcovd@faf.cuni.cz (D.H.)
- ⁶ Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Palackeho trida 1946/1, 612 00 Brno, Czech Republic; milan.malanik@seznam.cz (M.M.)
- ⁷ Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic; michaela.vaskova@uhk.cz (M.V.)
- ⁸ Department of Analytical Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Kralove, Czech Republic; novakoval@faf.cuni.cz (L.N.)
- * Correspondence: pour@faf.cuni.cz; Tel.: +420 495 067 277

Table of contents

Figure S1. ESI-HRMS spectrum of 9- <i>O</i> -demethyllycorenine (1).....	3
Figure S2. ECD data of 9- <i>O</i> -demethyllycorenine (1), and lycorenine	3
Figure S3. ¹ H NMR spectrum of 9- <i>O</i> -demethyllycorenine (1) in CDCl ₃	4
Figure S4. ¹³ C NMR spectrum of 9- <i>O</i> -demethyllycorenine (1) in CDCl ₃	4
Figure S5. gCOSY spectrum of 9- <i>O</i> -demethyllycorenine (1).....	5
Figure S6. gHSQC spectrum of 9- <i>O</i> -demethyllycorenine (1)	5
Figure S7. gHMBCAD spectrum of 9- <i>O</i> -demethyllycorenine (1).....	6
Figure S8. gH2BC spectrum of 9- <i>O</i> -demethyllycorenine (1)	6
Figure S9. NOESY spectrum of 9- <i>O</i> -demethyllycorenine (1)	7
Figure S10. ESI-HRMS spectrum of narciabduliine (2)	7
Figure S11. ¹ H NMR spectrum of narciabduliine (2) in CDCl ₃	8
Figure S12. ¹³ C NMR spectrum of narciabduliine (2) in CDCl ₃	8
Figure S13. gCOSY spectrum of narciabduliine (2).....	9
Figure S14. gHSQC spectrum (aromatic region) of narciabduliine (2)	9
Figure S15. gHSQC spectrum (aliphatic region) of narciabduliine (2).....	10
Figure S16. gHMBCAD spectrum of narciabduliine (2).....	10
Figure S17. gH2BC spectrum of narciabduliine (2).....	11
Figure S18. NOESY spectrum of narciabduliine (2).....	11
Figure S19. Stacked plot of dynamic NMR analysis of narciabduliine (2) at different temperatures (CDCl ₃).....	12

Figure S1. ESI-HRMS spectrum of 9-*O*-demethyllycorenine (**1**)

304.1543

2020 12 29 06-100 A 722 (1.255) Cm (679:762-(124:397+1279:1692))

1: TOF MS ES+

2.62e6






Figure S2. ECD data of 9-*O*-demethyllycorenine (**1**), and lycorenine



9-*O*-demethyllycorenine



lycorenine

Figure S3. ^1H NMR spectrum of 9-O-demethyllycorenine (**1**) in CDCl_3




Figure S4. ^{13}C NMR spectrum of 9-O-demethyllycorenine (**1**) in CDCl_3




Figure S5. gCOSY spectrum of 9-O-demethyllycorenine (1)




Figure S6. gHSQC spectrum of 9-O-demethyllycorenine (1)




Figure S7. gHMBCAD spectrum of 9-O-demethyllycorenine (1)




Figure S8. gH2BC spectrum of 9-O-demethyllycorenine (1)




Figure S9. NOESY spectrum of 9-O-demethyllycorenine (1)




Figure S10. ESI-HRMS spectrum of narciabduliine (2)

541.2697

2020 12 29 06-097 B 1691 (2.913) Cm (1679:1717-(1581:1622+1762:1829))

1: TOF MS ES+
6.31e6




Figure S11. ^1H NMR spectrum of narciabduliine (2) in CDCl_3




Figure S12. ^{13}C NMR spectrum of narciabduliine (2) in CDCl_3




Figure S13. gCOSY spectrum of narciabduliine (2)




Figure S14. gHSQC spectrum (aromatic region) of narciabduliine (2)




Figure S15. gHSQC spectrum (aliphatic region) of narciabduliine (2)




Figure S16. gHMBCAD spectrum of narciabduliine (2)




Figure S17. gH2BC spectrum of narciabduliine (2)




Figure S18. NOESY spectrum of narciabduliine (2)




Figure S19. Stacked plot of dynamic NMR analysis of narciabduliine (**2**) at different temperatures (CDCl_3)

